A Phase 1 interventional study of Apixaban in Thromboembolism, sponsored by Bristol-Myers Squibb. Completed at 27 sites in 5 countries. Open to participants aged 1 Day to 18 Years. Per ClinicalTrials.gov, last updated 2021-03-22.
Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 78 studies in Thromboembolism with a site in United States — 8 open to participants now, 11 under way, 1 of them phase 3. Thromboembolism · United States.
Among the 78 studies in Thromboembolism with a site in United States, this one is the 42nd largest by enrollment of the 53 interventional ones that give a count, is the only one that started in 2013, is one of 4 in phase 1, and was the 37th registered.
288 studies on the registry are indexed under Thromboembolism; 42 are open to participants now.
Browse Thromboembolism studies →8 of the 78 studies in Thromboembolism with a site in United States are open now. Recruiting first, the newest first:
Imperative Care, Inc. · Sites in United States
Ages 18+
Quercis Pharma AG · Sites in United States
Ages 18+
Rushad Patell · Sites in United States
Ages 18+
Kristen Ban · Sites in United States
Ages 18–100
University of Arkansas · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 32 Thromboembolism studies recruiting now, 23 (72%) set no upper age limit and 4 (13%) stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.
This study: 1 Day to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
78 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 9 · Phase 3 22 · Phase 4 6
First in 1996; this study’s year is marked. 1 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 49 is below the median of 173 across 155 interventional studies indexed under Thromboembolism.
Median enrollment 192 across the 53 interventional studies, 200 across the 23 observational. Of the 64 that completed or were terminated, 33 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
31 of 78 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
Bristol-Myers Squibb has 4 studies filed under Thromboembolism — fewer than ten, so there is no comparison to draw.
6 of the studies in Thromboembolism with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06861088Phase 3Quercis Pharma AGThe Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer | 2027-10-31 |
| NCT05301348University of ArkansasIn Vivo Detection of Circulating Clots in Patients With Thromboembolism | 2026-12-31 |
| NCT05794165Bryan CottonAntithrombin to Improve Thromboprophylaxis and Reduce the Incidence of Trauma-Related Venous Thromboembolism | 2027-04 |
| NCT06886516Rushad PatellApixaban in Thrombocytopenia | 2027-07-01 |
| NCT06657924Kristen BanPreoperative Tranexamic Acid (TXA) to Prevent Bleeding in Patients Undergoing Major Colorectal Surgery | 2027-09-01 |
Add all 6 to your calendar (.ics) → With an account.
Among the 78 studies in Thromboembolism with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
CV185118 is a single dose Apixaban PK/PD study in pediatric participants. The objective of this study is primarily to study the PK/PD of Apixaban in pediatric participants at risk for thrombosis
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com
Inclusion Criteria:
Neonates ≥ 34 weeks gestational or ≥ 37 weeks post conceptual age (corrected gestational age) to \<18 years of age
Exclusion Criteria:
Drug: Apixaban
Drug: Apixaban
Drug: Apixaban
Drug: Apixaban
Drug: Apixaban
Drug: Apixaban
Drug: Apixaban
Specified dose on specified days
Also known as: BMS-562247
Estimated area under the plasma concentration-time curve [AUC(INF)] of Apixaban
Time frame: Up to 26 hours, post dose (from Day 1 to Day 2)
Maximum estimated plasma concentration (Cmax) of Apixaban
Time frame: Up to 26 hours, post dose (from Day 1 to Day 2)
Estimated time at which maximum plasma concentration occurs (Tmax) of Apixaban
Time frame: Up to 26 hours, post dose (from Day 1 to Day 2)
Number of participants with Adverse Events (AEs)
Time Frame: From Day 1 to Day 2 (Up to 26 hours, post dose), and 30 Day after last dosing
Time frame: Up to 30 Days after last dosing
Number of participants with Serious Adverse Events (SAEs)
Time Frame: From Day 1 to Day 2 (Up to 26 hours, post dose), and 30 Day after last dosing
Time frame: Up to 30 Days after last dosing
Change from baseline in Vital Signs of body temperature
Time Frame: From Day 1 to Day 2 (Up to 26 hours, post dose), and 30 Day after last dosing
Time frame: Up to 30 Days after last dosing
Change from baseline in Vital Signs of respiratory rate
Time Frame: From Day 1 to Day 2 (Up to 26 hours, post dose), and 30 Day after last dosing
Time frame: Up to 30 Days after last dosing
Change from baseline in Vital Signs of blood pressure
Time Frame: From Day 1 to Day 2 (Up to 26 hours, post dose), and 30 Day after last dosing
Time frame: Up to 30 Days after last dosing
Change from baseline in Vital Signs of heart rate
Time Frame: From Day 1 to Day 2 (Up to 26 hours, post dose), and 30 Day after last dosing
Time frame: Up to 30 Days after last dosing
Number of participants with abnormalities in Physical Examinations
Time Frame: From Day 1 to Day 2 (Up to 26 hours, post dose), and 30 Day after last dosing
Time frame: Up to 30 Days after last dosing
Change from baseline in Clinical Laboratory Tests of blood
Time Frame: From Day 1 to Day 2 (Up to 26 hours, post dose), and 30 Day after last dosing
Time frame: Up to 30 Days after last dosing
Change from baseline in Clinical Laboratory Tests of blood serum
Time Frame: From Day 1 to Day 2 (Up to 26 hours, post dose), and 30 Day after last dosing
Time frame: Up to 30 Days after last dosing
Change from baseline in Activated partial thromboplastin time (aPTT) clotting activity during treatment
Time Frame: From Day 1 to Day 2 (Up to 26 hours, post dose), and 30 Day after last dosing
Time frame: Up to 30 Days after last dosing
Change from baseline in International Normalized Ratio (INR) clotting activity during treatment
Time Frame: From Day 1 to Day 2 (Up to 26 hours, post dose), and 30 Day after last dosing
Time frame: Up to 30 Days after last dosing
Change from baseline in Prothrombin Time (PT) clotting activity during treatment
Time Frame: From Day 1 to Day 2 (Up to 26 hours, post dose), and 30 Day after last dosing
Time frame: Up to 30 Days after last dosing
Change from baseline in Clinical Laboratory Tests of urine
Time Frame: From Day 1 to Day 2 (Up to 26 hours, post dose), and 30 Day after last dosing
Time frame: Up to 30 Days after last dosing
Pharmacodynamics will be analyzed using anti-Factor Xa activity
Time frame: Up to 26 hours, post dose (from Day 1 to Day 2)
Ran from Jan 2013 to primary completion in Jun 2020, 89 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Apixaban